DelMar Pharmaceuticals Announces Acquisition and $5.4 Million Private Placement to Advance Novel Cancer Therapies January 25, 2013 • 12:50 PM EST
DelMar Pharmaceuticals to Present Interim Clinical Data on VAL-083 in Refractory Glioblastoma at Society for Neuro-Oncology (SNO) Annual Meeting November 15, 2012 • 12:00 AM EST
DelMar CEO Delivers Keynote Address at International Drug Discovery Science and Technology Conference November 8, 2012 • 12:00 AM EST
DelMar Pharmaceuticals Expands Collaboration with Guangxi Wuzhou Pharmaceutical Company October 29, 2012 • 12:00 AM EDT
DelMar Pharmaceuticals Named to the “Ready to Rocket” List for the Second Year in a Row February 28, 2012 • 12:00 AM EST
DelMar Pharmaceuticals to Present New Pre-clinical Data Related to the Mechanism of VAL-083 at the AACR Annual Meeting in April 2012 February 7, 2012 • 12:00 AM EST
DelMar Pharmaceuticals Granted U.S. Orphan Drug Designation for VAL-083 for the Treatment of Glioma February 2, 2012 • 12:00 AM EST
DelMar Pharmaceuticals Receives FDA IND Approval to Begin Clinical Trials with a New Brain Cancer Treatment September 6, 2011 • 12:00 AM EDT